Financial Engines Advisors
FATE icon

Financial Engines Advisors’s Fate Therapeutics FATE Stock Holding History

Financial Engines Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,992
Closed -$13.2K – 560
2026
Q1 		$13.2K Buy
+10,992
New +$13.4K ﹤0.01% 530
2025
Q3 		– Sell
-10,072
Closed -$11.2K – 553
2025
Q2 		$11.2K Sell
10,072
-1
-0% -$1 ﹤0.01% 517
2025
Q1 		$7.93K Buy
+10,073
New +$12.3K ﹤0.01% 429

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Financial Engines Advisors's FATE Position: Q2 2026 in Review

Financial Engines Advisors sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 10,992 shares — an estimated $13.2K sold.

Financial Engines Advisors first reported a position in FATE in Q1 2025 and held it in 3 quarters. The position peaked at $13.2K in Q1 2026. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Financial Engines Advisors reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Financial Engines Advisors sold 10,992 Fate Therapeutics shares in Q2 2026, an estimated $13.2K.
  • Financial Engines Advisors first reported a position in Fate Therapeutics in Q1 2025 and held it in 3 quarters.
  • Financial Engines Advisors's Fate Therapeutics position peaked at $13.2K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Financial Engines Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.